Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018

Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016

Mie Ikeda, Megumi Kaneko, Shin-Ichiro Tachibana, Betty Balikagala, Miki Sakurai-Yatsushiro, Shouki Yatsushiro, Nobuyuki Takahashi, Masato Yamauchi, Makoto Sekihara, Muneaki Hashimoto1, Osbert T. Katuro2, Alex Olia3, Paul S. Obwoya, Mary A. Auma, Denis A. Anywar, Emmanuel I. Odongo-Aginya, Joseph Okello-Onen4, Makoto Hirai, Jun Ohashi, Nirianne M.Q. Palacpac, Masatoshi Kataoka, Takafumi Tsuboi, Eisaku Kimura, Toshihiro Horii, and Toshihiro MitaComments to Author 
Author affiliations: Juntendo University School of Medicine, Tokyo, Japan (M. Ikeda, M. Kaneko, S.-I. Tachibana, M. Yamauchi, M. Sekihara, M. Hashimoto, M. Hirai, T. Mita); Ehime University, Matsuyama, Japan (B. Balikagala, T. Tsuboi); Tokyo Women’s Medical University, Tokyo (M. Sakurai-Yatsushiro, N. Takahashi); National Institute of Advanced Industrial Science and Technology, Kagawa, Japan (S. Yatsushiro, M. Kataoka); Med Biotech Laboratories, Kampala, Uganda (O.T. Katuro); Gulu University, Gulu, Uganda (A. Olia, D.A. Anywar, E.I. Odongo-Aginya, J. Okello-Onen); St. Mary’s Hospital Lacor, Gulu (P.S. Obwoya, M.A. Auma); The University of Tokyo, Tokyo (J. Ohashi); Osaka University, Osaka, Japan (N.M.Q. Palacpac, E. Kimura, T. Horii)

Main Article

Table 1

Baseline characteristics of patients enrolled in study of Plasmodium falciparum ex vivo RSA survival rates, Uganda, 2014–2016*

Characteristics Enrolled RSA results obtained
No. patients 249 194
2014 Oct 16 15
2015 May 74 43
2015 Oct 63 51
2016 June
Sex, no. patients
M 126 92
Age, y
Median (IQR)
3.0 (2.0–4.5)
2.9 (2.0–4.4)
Fever >37.5°C
No. (%) patients 207 (83) 177 (92)
Median (IQR) body 
temperature, °C
39 (38.0–39.4)
39 (38.3–39.5)
Signs and symptoms, % patients
Cough 22 29
Vomiting 21 25
Abdominal pain 11 21
Headache 10 19
Diarrhea 7 10
Day 0 parasitemia, median (IQR), % 1.71 (0.17–4.13) 1.95 (0.85–4)

*IQR, interquartile range; RSA, ring-stage survival assay.

Main Article

1Current affiliation: National Institute of Advanced Industrial Science and Technology, Kagawa, Japan.

2Current affiliation: Mildmay Uganda-KAMPALA, Kampala, Uganda.

3Current affiliation: Gunma University, Gunma, Japan.


Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.